Browse BCL2L1

Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform Bcl-X(L): Mitochondrion inner membrane Mitochondrion outer membrane Mitochondrion matrix Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Cytoplasm, cytosol Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus membrane Single-pass membrane protein Cytoplasmic side Note=After neuronal stimulation, translocates from cytosol to synaptic vesicle and mitochondrion membrane in a calmodulin-dependent manner (By similarity). Localizes to the centrosome when phosphorylated at Ser-49.
Domain PF00452 Apoptosis regulator proteins
PF02180 Bcl-2 homology region 4
Function

Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.; FUNCTION: Isoform Bcl-X(L) also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F(1)F(0) activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. May attenuate inflammation impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785). ; FUNCTION: Isoform Bcl-X(S) promotes apoptosis.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000910 cytokinesis
GO:0001101 response to acid chemical
GO:0001541 ovarian follicle development
GO:0001701 in utero embryonic development
GO:0001836 release of cytochrome c from mitochondria
GO:0006839 mitochondrial transport
GO:0007006 mitochondrial membrane organization
GO:0007009 plasma membrane organization
GO:0007093 mitotic cell cycle checkpoint
GO:0007281 germ cell development
GO:0007283 spermatogenesis
GO:0007346 regulation of mitotic cell cycle
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0008585 female gonad development
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0008637 apoptotic mitochondrial changes
GO:0009314 response to radiation
GO:0009566 fertilization
GO:0009615 response to virus
GO:0010212 response to ionizing radiation
GO:0010332 response to gamma radiation
GO:0010639 negative regulation of organelle organization
GO:0010821 regulation of mitochondrion organization
GO:0010823 negative regulation of mitochondrion organization
GO:0019048 modulation by virus of host morphology or physiology
GO:0019050 suppression by virus of host apoptotic process
GO:0019054 modulation by virus of host process
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0022602 ovulation cycle process
GO:0033668 negative regulation by symbiont of host apoptotic process
GO:0035821 modification of morphology or physiology of other organism
GO:0038034 signal transduction in absence of ligand
GO:0039526 modulation by virus of host apoptotic process
GO:0042391 regulation of membrane potential
GO:0042698 ovulation cycle
GO:0043200 response to amino acid
GO:0043279 response to alkaloid
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0044003 modification by symbiont of host morphology or physiology
GO:0044068 modulation by symbiont of host cellular process
GO:0044531 modulation of programmed cell death in other organism
GO:0044532 modulation of apoptotic process in other organism
GO:0045137 development of primary sexual characteristics
GO:0045786 negative regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0046545 development of primary female sexual characteristics
GO:0046546 development of primary male sexual characteristics
GO:0046660 female sex differentiation
GO:0046661 male sex differentiation
GO:0046898 response to cycloheximide
GO:0046902 regulation of mitochondrial membrane permeability
GO:0048232 male gamete generation
GO:0048511 rhythmic process
GO:0048608 reproductive structure development
GO:0051402 neuron apoptotic process
GO:0051701 interaction with host
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051881 regulation of mitochondrial membrane potential
GO:0052040 modulation by symbiont of host programmed cell death
GO:0052041 negative regulation by symbiont of host programmed cell death
GO:0052150 modulation by symbiont of host apoptotic process
GO:0052248 modulation of programmed cell death in other organism involved in symbiotic interaction
GO:0052433 modulation by organism of apoptotic process in other organism involved in symbiotic interaction
GO:0052490 negative regulation by organism of programmed cell death in other organism involved in symbiotic interaction
GO:0060154 cellular process regulating host cell cycle in response to virus
GO:0061458 reproductive system development
GO:0070584 mitochondrion morphogenesis
GO:0070997 neuron death
GO:0071214 cellular response to abiotic stimulus
GO:0071229 cellular response to acid chemical
GO:0071230 cellular response to amino acid stimulus
GO:0071312 cellular response to alkaloid
GO:0071417 cellular response to organonitrogen compound
GO:0071478 cellular response to radiation
GO:0071479 cellular response to ionizing radiation
GO:0071480 cellular response to gamma radiation
GO:0071839 apoptotic process in bone marrow
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090003 regulation of establishment of protein localization to plasma membrane
GO:0090005 negative regulation of establishment of protein localization to plasma membrane
GO:0090150 establishment of protein localization to membrane
GO:0090199 regulation of release of cytochrome c from mitochondria
GO:0090201 negative regulation of release of cytochrome c from mitochondria
GO:0090559 regulation of membrane permeability
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097194 execution phase of apoptosis
GO:0097284 hepatocyte apoptotic process
GO:0097305 response to alcohol
GO:0098586 cellular response to virus
GO:1900117 regulation of execution phase of apoptosis
GO:1900118 negative regulation of execution phase of apoptosis
GO:1901099 negative regulation of signal transduction in absence of ligand
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901654 response to ketone
GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage
GO:1902532 negative regulation of intracellular signal transduction
GO:1903076 regulation of protein localization to plasma membrane
GO:1903077 negative regulation of protein localization to plasma membrane
GO:1903729 regulation of plasma membrane organization
GO:1903828 negative regulation of cellular protein localization
GO:1904019 epithelial cell apoptotic process
GO:1904375 regulation of protein localization to cell periphery
GO:1904376 negative regulation of protein localization to cell periphery
GO:1904950 negative regulation of establishment of protein localization
GO:1990778 protein localization to cell periphery
GO:2001020 regulation of response to DNA damage stimulus
GO:2001021 negative regulation of response to DNA damage stimulus
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand
GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand
GO:2001242 regulation of intrinsic apoptotic signaling pathway
GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
GO:2001244 positive regulation of intrinsic apoptotic signaling pathway
Molecular Function GO:0046982 protein heterodimerization activity
GO:0051400 BH domain binding
GO:0051434 BH3 domain binding
GO:0070513 death domain binding
Cellular Component GO:0005635 nuclear envelope
GO:0005741 mitochondrial outer membrane
GO:0005743 mitochondrial inner membrane
GO:0005759 mitochondrial matrix
GO:0005813 centrosome
GO:0008021 synaptic vesicle
GO:0019867 outer membrane
GO:0030133 transport vesicle
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030672 synaptic vesicle membrane
GO:0031965 nuclear membrane
GO:0031968 organelle outer membrane
GO:0070382 exocytic vesicle
GO:0097136 Bcl-2 family protein complex
GO:0098793 presynapse
GO:0099501 exocytic vesicle membrane
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04140 Regulation of autophagy
hsa04151 PI3K-Akt signaling pathway
hsa04210 Apoptosis
hsa04621 NOD-like receptor signaling pathway
hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-109581: Apoptosis
R-HSA-111453: BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-622312: Inflammasomes
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-109606: Intrinsic Pathway for Apoptosis
R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
R-HSA-5357801: Programmed Cell Death
R-HSA-449147: Signaling by Interleukins
R-HSA-844455: The NLRP1 inflammasome
Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BCL2L1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BCL2L1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
10697273Central nervous system lymphomaInhibit immunityOverexpression of BCL-2, BCL-X, and BAX in primary central nervous system lymphomas that occur in immunosuppressed patients.
19454669LymphomaPromote immunity (T cell function)In vivo, with response to tumor-expressed Ag following adoptive T cell transfer, Ag-reactive CD8(+) T cells expressing both Bcl-x(L) and survivin displayed greatly enhanced tumor protective activity compared with CD8(+) T cells expressing either molecule introduced separately. These results indicate that Bcl-x(L) and survivin can critically contribute in a cooperative, nonredundant manner to augment the accumulation and persistence of CD8(+) T cells following encounter with Ag.
16148096ThymomaPromote immunityOX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. The lack of OX40 costimulation was associated with reduced levels of Bcl-x(L), and retroviral expression of Bcl-x(L) in tumor-reactive CD8 T cells conferred greatly enhanced tumor protection following adoptive transfer.
25070854lymphomaPromote immunityWe found that overexpression or induction of Bcl-xL led to increased Ag presentation to NKT cells. Conversely, the inhibition or knockdown of Bcl-xL led to decreased NKT cell activation.
Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BCL2L1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BCL2L1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.150.514
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.660.803
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2190.908
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6450.0448
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7540.705
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5090.843
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2340.591
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1630.926
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6980.722
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0290.989
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0470.988
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.020.798
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BCL2L1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BCL2L1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BCL2L1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BCL2L1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BCL2L1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BCL2L1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BCL2L1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBCL2L1
NameBCL2-like 1
Aliases BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location20q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BCL2L1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting BCL2L1.
ID Name Drug Type Targets #Targets
DB071084'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACIDSmall MoleculeBCL2L11
DB09401IsosorbideSmall MoleculeBCL2, BCL2L1, MCL13
DB13044GossypolSmall MoleculeBCL2L11